Study Finds CBG Extracts More Stable Than CBD in Topical Formulations

CBG Stability Advantage in Topical Products

CBG extracts maintained higher potency and chemical integrity than CBD extracts when formulated into topical bases and subjected to accelerated aging protocols. The study tested both cannabinoids in oil-in-water emulsions at varying concentrations. Result: CBG degraded 23% slower than CBD under identical storage conditions over a 90-day period.

The stability differential matters for manufacturers making label claims. A product formulated with 500 mg CBG per container retains therapeutic concentration longer than an equivalent CBD formulation, which reduces the risk of potency drift that triggers FDA warning letters under 21 CFR Part 111 (current good manufacturing practice for dietary supplements).

Antioxidant and Antimicrobial Performance

Both CBD and CBG extracts demonstrated statistically significant antioxidant activity, with CBG showing a 12% higher free-radical scavenging capacity in DPPH assays. Antimicrobial testing revealed activity against common skin pathogens, including Staphylococcus aureus and Cutibacterium acnes, at concentrations as low as 0.5% by weight.

Key performance metrics from the study:

• CBG DPPH IC50: 18.3 μg/mL
• CBD DPPH IC50: 20.7 μg/mL
• Minimum inhibitory concentration for S. aureus: 0.5% (both cannabinoids)
• CBG photostability: 77% retention after 72-hour UV exposure
• CBD photostability: 61% retention under identical conditions

Regulatory and Formulation Implications

The stability data provides manufacturers with a compliance pathway for extending shelf-life claims without triggering new drug application requirements under the Federal Food, Drug, and Cosmetic Act. Hemp-derived cannabinoids in cosmetics fall under FDA's Office of Cosmetics and Colors jurisdiction, not the Center for Drug Evaluation and Research, provided manufacturers make no disease-treatment claims.

CBG's slower oxidation rate means formulators can reduce preservative loads or extend expiration dating. That margin matters in states like California, where Proposition 65 disclosure thresholds for certain antioxidants create labeling friction.

Market and R&D Context

CBG isolate currently trades at $800-$1,200 per kilogram wholesale, roughly double the price of CBD isolate. This makes the stability advantage economically relevant for premium skincare lines. The cost differential narrows when calculating cost-per-stable-dose over product shelf life.

For full background on cannabinoid research and regulatory frameworks, see the CannIntel topic hub on CBD and CBG research. What's next? Whether the FDA issues updated guidance on cannabinoid cosmetics before the end of 2026, a move the agency has signaled in recent Federal Register notices.